$CLLS News
Last published 2d ago
- 2d agoCLLSCellectis to Report Third Quarter Financial Results on November 12, 2026GlobeNewswireNEW YORK, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a genome engineering company developing genetic medicines for diseases that today demand a lifetime of treatment, will
- 2d agoCLLSCellectis to Report Third Quarter Financial Results on November 12, 2026GlobeNewswireNEW YORK, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a genome engineering company developing genetic medicines for diseases that today demand a lifetime of treatment, will report financial results for the third quarter 2026 ending September 30, 2026 on Thursday, November 12, 2026 after the close of the U.S. market.
- 2w agoCLLSCellectis Presents Preclinical Data Highlighting Efficient APOC3 Editing and Marked Triglyceride Reduction with .HEAL-101 at ESGCT 2026GlobeNewswire70% in vivo editing of human APOC3 in a single administration76% triglyceride reduction after a single dose in murine disease model NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Cellectis (NASDAQ:CLLS), a genome
- 1mo agoCLLSCellectis Live Conference Call - French Session - CELLECTIS SAEarnings Call TranscriptsBonjour Mesdames et Messieurs et bienvenue à la conférence téléphonique Selectus. Pour l'instant, toutes les lignes sont en mode écoute seulement. Après la présentation, nous procéderons à une séance de questions et répo
- 1mo agoCLLSCellectis Live Conference Call - English Session - CELLECTIS SAEarnings Call TranscriptsGood morning, ladies and gentlemen. Welcome to the Selectus live conference call English session. At this time, all lines are in a listen-only mode. Following presentation, we will conduct a question and answer session.
- 1mo agoCLLSCellectis Announces Strategic Transformation To In Vivo Gene Editing CompanyGlobeNewswireCellectis to advance two lead in vivo programs .HEAL-101 and .HEAL-201 in severe dyslipidemias with preliminary Phase 1 data planned in H2 2027 and H1 2028, respectivelyTransformation supported by continuing existing
- 2mo agoCLLSCellectis to Host Conference Call and Webcast on September 14 to Provide a Business UpdateGlobeNewswireNEW YORK, Sept. 11, 2026 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene
- 2mo agoCLLSCellectis Announces Participation in Upcoming Investor ConferencesGlobeNewswireNEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene
- 3mo agoCLLSCellectis Reports Financial Results for the Second Quarter 2026GlobeNewswireLasme-cel: Pivotal Phase 2 in r/r B-ALL (BALLI-01) FDA RMAT designation received for lasme-cel Full Phase 1 clinical data from the BALLI-01 trial presented at EHA 2026 Pivotal Phase 2 first interim analysis expected
- 3mo agoCLLSCellectis to Report Second Quarter Financial Results on August 6, 2026GlobeNewswireNEW YORK, July 30, 2026 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene
- 3mo agoMGXCLLSProlynx Names Simon Harnest as Chief Financial Officer and Amer Mirza, PhD, as Chief Scientific Officer as It Advances Multi-Program Obesity and Metabolic Disease PortfolioGlobeNewswireEMERYVILLE, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Prolynx, a biotechnology company developing a next-generation portfolio of ultra-long-acting medicines for obesity and related metabolic conditions, today
- 5mo agoCLLSCellectis Presents Final Phase 1 Results of Lasme-cel and Preliminary Results on Eti-cel at EHA 2026 CongressGlobeNewswireNEW YORK, June 11, 2026 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies,
- 5mo agoCLLSCellectis Receives FDA RMAT Designation for lasme-cel, the First Allogeneic CAR-T Therapy in a Pivotal Trial for Patients with r/r B-ALLGlobeNewswireNEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies,
- 5mo agoCLLSCellectis' Annual Shareholders General Meeting to be Held on June 25, 2026GlobeNewswireNEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies,
- 6mo agoCLLSCellectis to Present Clinical Data on Lasme-cel and Eti-cel at EHA 2026 Annual CongressGlobeNewswireNEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies,
- 6mo agoCLLSCellectis Reports Financial Results for the First Quarter 2026GlobeNewswirePivotal Phase 2 with lasme-cel in r/r B-ALL (BALLI-01 trial) Pivotal Phase 2 first interim analysis expected in Q4 2026BLA submission anticipated in 2028 Phase 1 with eti-cel in r/r NHL (NATHALI-01 trial) Full Phase
- 6mo agoCLLSCellectis to Report First Quarter Financial Results on May 11, 2026GlobeNewswireNEW YORK, May 04, 2026 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies,
- 6mo agoCLLSCellectis Presents Epigenetic Editing Platform to Turn Genes Off Without Altering DNA at the ASGCT Annual MeetingGlobeNewswireNEW YORK, April 27, 2026 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies,
- 7mo agoCLLSCema-Cel Pivotal Trial Interim Data Highlight Strength of Cellectis' Allogeneic CAR-T PlatformGlobeNewswireNEW YORK, April 13, 2026 (GLOBE NEWSWIRE) -- Cellectis (or the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies,
- 8mo agoCLLSCellectis to Report Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026GlobeNewswireNEW YORK, March 12, 2026 (GLOBE NEWSWIRE) -- Cellectis (the "Company") ((Euronext Growth: ALCLS, NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving
- 10mo agoCLLSCellectis Announces 2026 Strategy and CatalystsGlobeNewswireNEW YORK, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies,
- 11mo agoALLOCLLSAllogene Therapeutics Reports Favorable Result for Servier in Arbitration with CellectisGlobeNewswireArbitration Ruling Reaffirms Allogene's Full Control of Cemacabtagene Ansegedleucel (Cema-Cel)Decision Reconfirms Allogene's Expanded Sub-License Covering EU and UK Rights with Options for Japan and China, Clearing the
- 11mo agoCLLSCellectis Announces Arbitral Decision in Dispute with ServierGlobeNewswireNEW YORK, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies,
- 11mo agoCLLSASH 2025: Cellectis Presents Development Plan to Further Enhance High Response Rate Observed for Eti-cel in r/r NHLGlobeNewswireEti-cel showed an 88% ORR and 63% CR (n=8) at current dose level in r/r NHL after ≥2 prior lines of therapyIn vivo data suggest IL-2 may further enhance response rates and optimize eti-cel expansion and persistenceIL-2
- 11mo agoCLLSCellectis Publishes Nature Communications Article on a Non-Viral Gene Editing Process Enabling Efficient Gene Insertion in Hematopoietic Stem CellsGlobeNewswireNEW YORK, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies,
- 1y agoCLLSCellectis Reports Third Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswirePresented data underscore the potential of lasme-cel (UCART22) and eti-cel (UCART20x22) to improve outcomes in r/r B-ALL and r/r NHL: Lasme-cel in r/r B-ALL (BALLI-01) ORR of 68% with lasme-cel Process 2 (n=22), 83%
- 1y agoCLLSCellectis to Present a Development Update for eti-cel at ASH 2025GlobeNewswirePreliminary data recently shared for eti-cel (UCART20x22) show an 86% ORR and a 57% CR rate (n=7), underscoring its potential to improve outcomes in r/r NHLPreclinical data demonstrated that combining eti-cel with
- 1y agoCLLSCellectis to Report Third Quarter Financial Results on November 7, 2025GlobeNewswireNEW YORK, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies,
- 1y agoCLLSCellectis' R&D Day Highlights Lasme-cel's Potential to Address Significant Unmet Need for Patients with r/r B-ALLGlobeNewswire○ Efficacy: ORR of 68% with lasme-cel Process 2 (n=22), 83% at RP2D (n=12) and 100% in the target Phase 2 population (n=9) ○ Safety: in Phase 1 (n=40), lasme-cel was generally well-tolerated (including 1 case of grade
- 1y agoCLLSCellectis Hosts R&D Day Today Showcasing Pipeline Progress and Long-Term Value DriversGlobeNewswireEvent features full Phase 1 data and pivotal Phase 2 strategy for lasme-cel (UCART22) in r/r B-ALL NEW YORK, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology
- 1y agoCLLSCellectis to Present Data on Non-Viral Gene Therapy and TALE Base Editors at the ESGCT Annual CongressGlobeNewswireNEW YORK, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies,
- 1y agoCLLSCellectis S.A. (CLLS) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoCLLSCellectis Reports Second Quarter 2025 Financial Results & Business UpdatesGlobeNewswireCellectis to host an Investor R&D Day in New York City on October 16, 2025: Phase 1 dataset and late-stage development strategy for lasme-cel (UCART22) in r/r B-ALL to be presented End-of-Phase 1 meetings with FDA
- 1y agoCLLSCellectis to Report Second Quarter 2025 Financial Results on August 4, 2025GlobeNewswireNEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies,
- 1y agoCLLSCellectis Reports Results from Shareholders Meeting Held on June 26, 2025GlobeNewswireNEW YORK, June 26, 2025 (GLOBE NEWSWIRE) -- Cellectis ((Euronext Growth: ALCLS, NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene
- 1y agoCLLSCellectis' Annual Shareholders General Meeting to be Held on June 26, 2025GlobeNewswireNEW YORK, May 21, 2025 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies,
- 1y agoCLLSCellectis Reports Financial Results for the First Quarter 2025GlobeNewswireLasme-cel (UCART22) Phase 1 dataset and late-stage development strategy expected in the third quarter of 2025Eti-cel (UCART20x22) Phase 1 study in relapsed or refractory B-cell non-Hodgkin lymphoma (r/r NHL) ongoing with
- 1y agoCLLSCellectis to Report First Quarter Financial Results on May 12, 2025GlobeNewswireNEW YORK, May 06, 2025 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies,
- 1y agoCLLSCellectis Presents Non-Viral Gene Editing and Base Editing Innovation at the ASGCT Annual MeetingGlobeNewswireNEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies,
- 1y agoCLLSCellectis Reports Financial Results for the Fourth Quarter and Full Year 2024 and Provides a Business UpdateGlobeNewswire○ UCART22 Phase 1 dataset and late-stage development strategy expected in the third quarter of 2025; Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) granted by FDA and ODD granted by the
- 1y agoCLLSCellectis to Report Fourth Quarter and Full Year 2024 Financial Results on March 13, 2025GlobeNewswireNEW YORK, March 07, 2025 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies,
- 1y agoCLLSCellectis Presents 'Smart CAR T' Strategy to Enhance Efficacy Against Solid Tumors at AACR-IO 2025GlobeNewswireNEW YORK, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies,
- 1y agoCBUSCLLSMGXCLXTTotus Medicines Appoints Simon Harnest, MSc, BSc, as Chief Financial OfficerGlobeNewswireEMERYVILLE, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Totus Medicines, a company revolutionizing small molecule drug discovery and development using covalent DNA-encoded libraries and AI tools, today announced the
- 1y agoCLLSCellectis announces the drawdown of the third tranche of €5 million under the credit facility agreement entered with the European Investment Bank (EIB)GlobeNewswireNEW YORK, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Cellectis (NASDAQ:CLLS) (the "Company"), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene
- 2y agoCLLSCellectis Presents Multiple Strategies to Enhance CAR T-cell Efficacy in Solid Tumors at the SITC Annual MeetingGlobeNewswireNEW YORK, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies,
- 2y agoCLLSCellectis S.A. (CLLS) Q3 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoCLLSCellectis Provides Business Updates and Financial Results for Third Quarter 2024GlobeNewswireUCART22 and UCART20x22: enrollment ongoing, Phase 1 dataset and late-stage development strategy to be presented in 2025AstraZeneca partnership: R&D activities are ongoing on three programs – one allogeneic CAR T for
- 2y agoCLLSCellectis to Report Third Quarter 2024 Financial Results on November 4, 2024GlobeNewswireNEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies,
- 2y agoCLLSCellectis to Present Data on TALE-Base Editors and Non-Viral Gene Therapy at the ESGCT 31st Annual CongressGlobeNewswireNEW YORK, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies,
- 2y agoCLLSCellectis Presents Pre-Clinical Evidence of MUC1 CAR T-cells Reducing Triple-Negative Breast Cancer While Preserving SafetyGlobeNewswireNEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies,